Patients diagnosed with CRC are recommended to undergo screening for LS, which comprises tumour testing for the loss of expression (LOE) of one or more MMR proteins and/or high levels of microsatellite instability (collectively referred to as MMR-deficiency) [2, 4, 6–9]. The gene discussed is MRC1; the disease is mismatch repair cancer syndrome 1.